"label","description","id","name","uuid:ID","instanceType","rationale"
"","The main design for the study","StudyDesign_1","Study Design 1","1c8df708-68cf-4d55-b547-8e8fb8b5c1e2","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
